These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 32020475

  • 21. Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice.
    Carter TC, Medina-Flores R, Lawler BE.
    Biomed Res Int; 2018; 2018():6204676. PubMed ID: 30687753
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
    Yin AA, He YL, Etcheverry A, Liu YH, Aubry M, Barnholtz-Sloan J, Liu BL, Mosser J, Lu ZF, Zhang X.
    Clin Epigenetics; 2019 May 14; 11(1):76. PubMed ID: 31088577
    [Abstract] [Full Text] [Related]

  • 25. Temozolomide in glioblastoma treatment: 15-year clinical experience and analysis of its efficacy.
    Glavatskyi OY, Zemskova OV, Khmelnytskyi HV, Kardash KA, Shuba IM, Stuley VA.
    Exp Oncol; 2020 Jun 14; 42(2):148-156. PubMed ID: 32602292
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
    Toms SA, Kim CY, Nicholas G, Ram Z.
    J Neurooncol; 2019 Jan 14; 141(2):467-473. PubMed ID: 30506499
    [Abstract] [Full Text] [Related]

  • 31. Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme.
    Shields LB, Kadner R, Vitaz TW, Spalding AC.
    Radiat Oncol; 2013 Apr 25; 8():101. PubMed ID: 23618500
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis.
    Wang J, Huang Y, Zhao F, Chen J, He L, Liu Z, Pei Y, Wei Z, Li R, Ai P, Peng X.
    J Neurooncol; 2022 Nov 25; 160(2):433-443. PubMed ID: 36357822
    [Abstract] [Full Text] [Related]

  • 34. Hypofractionated re-irradiation with bevacizumab for relapsed chemorefractory glioblastoma after prior high dose radiotherapy: a feasible option for patients with large-volume relapse.
    Tong E, Horsley P, Wheeler H, Wong M, Venkatesha V, Chan J, Kastelan M, Back M.
    J Neurooncol; 2024 May 25; 168(1):69-76. PubMed ID: 38551747
    [Abstract] [Full Text] [Related]

  • 35. Is the Duration of Temozolomide Predictive for Sequential Bevacizumab Treatment Responses in the Glioblastoma Multiforme Cancer Setting?
    Besiroglu M, Demir T, Shbair ATM, Yasin AI, Topcu A, Turk HM.
    J Coll Physicians Surg Pak; 2021 Aug 25; 31(8):932-936. PubMed ID: 34320710
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
    Kickingereder P, Wiestler B, Burth S, Wick A, Nowosielski M, Heiland S, Schlemmer HP, Wick W, Bendszus M, Radbruch A.
    Neuro Oncol; 2015 Aug 25; 17(8):1139-47. PubMed ID: 25754089
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Temozolomide for patients with wild-type isocitrate dehydrogenase (IDH) 1 glioblastoma using propensity score matching.
    Tunthanathip T, Sangkhathat S.
    Clin Neurol Neurosurg; 2020 Apr 25; 191():105712. PubMed ID: 32036239
    [Abstract] [Full Text] [Related]

  • 40. Recurrent Glioblastoma: Combination of High Cerebral Blood Flow with MGMT Promoter Methylation Is Associated with Benefit from Low-Dose Temozolomide Rechallenge at First Recurrence.
    Kim C, Kim HS, Shim WH, Choi CG, Kim SJ, Kim JH.
    Radiology; 2017 Jan 25; 282(1):212-221. PubMed ID: 27428890
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.